Kat Marie Alvarez, RN, MBA, on execution credibility, structural discipline, and why strategy without clinical accountability is just theory
Kat Marie Alvarez, RN, MBA
Founder and CEO of KATALYST & Co., a healthcare transformation platform integrating clinical delivery, advisory services, and venture investment. With more than 25 years of experience spanning bedside nursing through C-suite leadership at organizations including Humana, Optum, Centene, Cano Health, and Innovacare Health, she has shaped strategy and operations with responsibility for billions in P&L and impact across more than 12 million lives. A Forbes Business Council member, ACHE CEO Circle Member, bestselling author, and national healthcare speaker, Kat builds organizations at the intersection of clinical rigor and sustainable growth.
ON ORIGIN AND STRUCTURE
Q
You have spent 25 years inside some of the most complex risk-bearing organizations in healthcare. What did you repeatedly see failing, and how did that shape how you built Katalyst Health from the ground up?
A
We started Katalyst Health in 2018 at the height of industry consolidation and investor interest. I had been consulting with several PE-backed companies, and what I kept seeing was a fundamental disconnect between those creating the strategies and those accountable for delivering care. I worked inside environments where the plans were sophisticated, the intentions were genuine, and the talent was real; the structure, however, was misaligned. Advisory teams were giving guidance without operating under the same constraints as “the doers”. Capital was moving faster than systems could absorb. Clinical teams were being asked to execute decisions they had no hand in shaping. What caused failures was never intelligence or intent. It was structural inconsistencies that were created by a strategy that was not tactically sound.
That became the cornerstone of Katalyst Health. If clinical delivery is where healthcare risk concentrates, then clinical delivery must sit at the center of everything, not downstream of it. I wanted to build an organization where thinking (strategy) and doing (tactical execution) were never separated, where the people responsible for outcomes were the same people informing strategy and vice versa.
Q
Most platforms put clinical delivery downstream. You made it the center. Walk us through the decision to structure Katalyst Health and now Katalyst & Co. that way.
A
The default model in healthcare services is to lead with advisory or investment services, then attach clinical capacity as a proof point or add-on. That model works until it meets the reality of actual care delivery, where regulations, reimbursement, workforce constraints, and patient complexity collide.
I sequenced intentionally. Katalyst Health exists as the core of Katalyst & Co. because clinical delivery is the only place where you can test whether a strategy actually holds. When you start there, your advisory work is informed by real operating conditions rather than assumptions. Your investment thesis is shaped by what is feasible inside payer and regulatory frameworks, and no longer by abstract growth models. The clinical core forces discipline across the entire platform. Without it, you are building on theory, not real-world scenarios.
ON CLINICAL CREDIBILITY
Q
When you talk about execution credibility, what does that look like in a clinical environment? Can you give a real example of that, either from a payer or partner lens?
A
Execution credibility is the difference between being heard and being trusted. In healthcare, partners and payers have seen too many firms come in with polished decks and incomplete operating experience. The moment they realize you are accountable for outcomes the way they are, the conversation changes entirely.
I have been in rooms where a single question shifted everything: Have you ever held a risk-bearing contract? When the answer is yes, and you can speak to what quality looked like under that contract, how you managed utilization, what compliance demanded, and where it got hard, the dynamic changes. You are no longer a vendor. You are a peer. That is what execution credibility does. It earns you a seat at the table where decisions are made and where outcomes are driven.
Q
You have described moments in your career where strategy looked sound on paper but, unravelled during execution. What is the most common place that breakdown happens, and what does Katalyst Health do differently to prevent it?
A
The most common breakdown point is the gap between design and implementation, specifically when the people who designed the strategy are not present for implementation and have no accountability for what happens next. You see this constantly in healthcare transformation. A consulting team hands off a roadmap, and tracks progress only – updates here and there. There is no co-ownership for outcomes. In other cases, the handoff occurs, and they exit. The internal team, often under-resourced and working within constraints the consultants never fully understood, is left to reconcile a plan that was never built for real life scenarios. I call it the theory versus practice gap.
We prevent this gap by staying embedded. We do not design and disappear. Our advisory work is shaped by what we know to be true operationally, and our clinical operations are informed by what we learn at the strategic and tactical level. The loop stays closed. That is the structural difference. Taking founder-led enterprises and prepping them for scale through a sound operating engine.
Q
Value-based care gets talked about constantly, but very few organizations operate in it at the risk-bearing level. What does it take clinically to function in a risk-bearing provider, and what separates organizations that succeed from those that stall?
A
Operating in risk-bearing care requires a level of clinical discipline that most organizations underestimate until they are inside it. You need real-time visibility into utilization, tight care coordination across the continuum, proactive outreach for high-risk members, and a workforce that understands how clinical decisions translate into financial outcomes. Those capabilities do not develop overnight, and they cannot be bolted on.
What sets successful organizations apart is that they build the infrastructure before they need it. They invest in clinical leadership, data systems, and care management protocols before the financial pressure hits. The ones that stall tend to take on risk before they are operationally ready, then spend their energy managing the bleeding rather than building capability. Readiness has to precede ambition in this space. If you are already taking on risk and facing challenges, a reset might be in order.
ON INTEGRATING CLINICAL, ADVISORY, AND CAPITAL
Q
You have said capital can create downstream pressure when it is misaligned. What does that look like in practice, and how does keeping Katalyst’s Health division central, protect against potential misalignment?
A
Misaligned capital shows up as growth that outpaces the systems designed to support it. You bring on a large payer contract before your care management infrastructure can absorb the volume. You expand into a new market before your clinical workforce is in place. You acquire additional providers/locations before the tech stack is properly outfitted. The financial model looks compelling, but the operational reality creates pressure at every layer of the organization, on teams, on margins, and ultimately on patients.
By keeping Katalyst Health central, we have a constant reality check. Investment decisions at the Venture Studio level are grounded in what we know to be clinically feasible and operationally sound. We are not making bets on abstract growth potential. We are allocating capital based on demonstrated clinical capability. That discipline is built into the platform’s structure.
This allows scale to occur and mitigates, if not altogether, eliminates risk related to operational readiness.
Q
How do clinical outcomes at Katalyst Health influence investment decisions at the Venture Studio level? Can you walk through how data from care delivery shapes where you allocate capital?
A
Clinical outcomes are signals, not endpoints. When we see consistent results in a particular care model or patient population, that tells us something important about where the market is underserved and where a scaled solution could have a real impact. That signal moves upstream into investment decisions.
For example, if the care delivery data shows persistent gaps in member engagement for a specific chronic condition, we assess whether technology or service solutions are worth investing in. We are not sourcing deals from spreadsheets. We are sourcing them from operational reality. That is a fundamentally difference and more grounded investment approach. We make sure to look for good opportunities where we can add value based on our exspertise.